We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Dipeptidyl peptidase-4 inhibition to treat type 2 ...

Study results have validated that five routinely measured clinical values reliably identified patients with type 2 diabetes who had significantly different A1c responses to two important classes of ...

Across a broad swath of patients, short-term use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor appears to reduce the risk of major adverse cardiovascular events, most notably cardiovascular ...

SGLT2 inhibitors showed significantly improved mortality benefits compared with DPP-4 inhibitors in patients with diabetic kidney disease (DKD) in a large target trial emulation study that adds ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

(Reuters) - A class of diabetes drugs that include Merck & Co Inc's Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday. The FDA said it had identified ...

Updates to NICE type 2 diabetes treatment recommendations and how nurses in primary care can implement the changes safely and ...

The results suggest that dipeptidyl peptidase-4 (DDP-4) inhibitors, which are widely prescribed in Germany, are not a cost-effective option despite lower drug pricing compared with empagliflozin.

DPP-4 exists as a membrane-bound form, widely expressed and enzymatically active on numerous cell types and different vascular beds... ...as well as a soluble form ...

The authors say their findings align with other analyses showing the cost-effectiveness of sodium glucose co-transporter 2 (SGLT2) inhibitors. Empagliflozin, the sodium glucose co-transporter 2 (SGLT2 ...